Xavier Leleu
A5048560248- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Cancer Mechanisms and Therapy
- Acute Myeloid Leukemia Research
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- HIV/AIDS drug development and treatment
- Glycosylation and Glycoproteins Research
- Galectins and Cancer Biology
- Chemokine receptors and signaling
- PI3K/AKT/mTOR signaling in cancer
- Acute Lymphoblastic Leukemia research
- MicroRNA in disease regulation
- Phytochemical compounds biological activities
Inserm
2016-2025
Centre Hospitalier Universitaire de Poitiers
2016-2025
Laboratoire de Génétique Cellulaire
2016-2025
Université de Poitiers
2017-2025
Ischémie Reperfusion, Métabolisme et Inflammation Stérile en Transplantation
2024
Dana-Farber Cancer Institute
2005-2023
Hôpital Claude Huriez
2012-2023
Harvard University
2005-2023
Centre Hospitalier Universitaire de Lille
2011-2023
Centre Hospitalier Universitaire de Rennes
2014-2023
High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients multiple myeloma. Residual disease almost always present after and responsible relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy transplantation.We randomly assigned 614 younger than 65 years age who had nonprogressive first-line to either (10 mg per day first 3 months, increased 15 if tolerated) or placebo until The primary...
High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on use combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) this population have raised questions about role timing transplantation.
Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce risk disease progression or death in this population.
At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe pattern of tumor-acquired mutations, but their clinical relevance has yet be established.We performed whole-exome sequencing for 463 patients who presented with were enrolled onto National Cancer Research Institute Myeloma XI trial, whom complete cytogenetic outcome data...
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard in immunoglobulin-light-chain (AL) amyloidosis, but these two strategies have not compared a randomized study.
The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. immunomodulatory agent pomalidomide myeloma that is a proteasome inhibitor.Patients was inhibitor were randomly assigned receive (elotuzumab group) alone (control group). primary end point investigator-assessed progression-free survival.A total of 117 the group (60 patients) control (57 patients). After minimum...
Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall (OS). Some preliminary data suggest that bortezomib able overcome these parameters.A series of 507 patients newly diagnosed MM who received four cycles bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both del(17p).We found remain parameters, even the context...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
The aim of the International Myeloma Working Group was to develop practice recommendations for management multiple myeloma (MM) -related bone disease.An interdisciplinary panel clinical experts on MM and disease developed based published data through August 2012. Expert consensus used propose additional in situations where there were insufficient data. Levels evidence grades assigned approved by members.Bisphosphonates (BPs) should be considered all patients with receiving first-line...
This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).Three cohorts were enrolled treated elotuzumab (5.0, 10, 20 mg/kg intravenously) on days 1, 8, 15, 22 of a 28-day cycle the first two cycles, 1 15 each subsequent cycle; lenalidomide 25 mg orally [PO] to 21; 40 PO weekly. Dose-limiting toxicities (DLTs) assessed during cohort, clinical responses cycle. The five received up six cycles therapy; until disease...